These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
497 related articles for article (PubMed ID: 25723512)
1. Nucleic acid-based aptamers: applications, development and clinical trials. Kanwar JR; Roy K; Maremanda NG; Subramanian K; Veedu RN; Bawa R; Kanwar RK Curr Med Chem; 2015; 22(21):2539-57. PubMed ID: 25723512 [TBL] [Abstract][Full Text] [Related]
2. SELEX methods on the road to protein targeting with nucleic acid aptamers. Bayat P; Nosrati R; Alibolandi M; Rafatpanah H; Abnous K; Khedri M; Ramezani M Biochimie; 2018 Nov; 154():132-155. PubMed ID: 30193856 [TBL] [Abstract][Full Text] [Related]
3. Aptamers in hematological malignancies and their potential therapeutic implications. Ouyang W; Yu Z; Zhao X; Lu S; Wang Z Crit Rev Oncol Hematol; 2016 Oct; 106():108-17. PubMed ID: 27637356 [TBL] [Abstract][Full Text] [Related]
5. Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers. Yu Y; Liang C; Lv Q; Li D; Xu X; Liu B; Lu A; Zhang G Int J Mol Sci; 2016 Mar; 17(3):358. PubMed ID: 26978355 [TBL] [Abstract][Full Text] [Related]
6. Enhancing aptamer function and stability via in vitro selection using modified nucleic acids. Meek KN; Rangel AE; Heemstra JM Methods; 2016 Aug; 106():29-36. PubMed ID: 27012179 [TBL] [Abstract][Full Text] [Related]
7. Aptamers: from bench side research towards patented molecules with therapeutic applications. Majumder P; Gomes KN; Ulrich H Expert Opin Ther Pat; 2009 Nov; 19(11):1603-13. PubMed ID: 19852719 [TBL] [Abstract][Full Text] [Related]
9. Aptamers as therapeutic middle molecules. Nakamura Y Biochimie; 2018 Feb; 145():22-33. PubMed ID: 29050945 [TBL] [Abstract][Full Text] [Related]
10. Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application. Adachi T; Nakamura Y Molecules; 2019 Nov; 24(23):. PubMed ID: 31766318 [TBL] [Abstract][Full Text] [Related]
11. Aptamers as radiopharmaceuticals for nuclear imaging and therapy. Gijs M; Aerts A; Impens N; Baatout S; Luxen A Nucl Med Biol; 2016 Apr; 43(4):253-71. PubMed ID: 26746572 [TBL] [Abstract][Full Text] [Related]
12. Three decades of nucleic acid aptamer technologies: Lessons learned, progress and opportunities on aptamer development. Wang T; Chen C; Larcher LM; Barrero RA; Veedu RN Biotechnol Adv; 2019; 37(1):28-50. PubMed ID: 30408510 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic applications of DNA and RNA aptamers. Thiel KW; Giangrande PH Oligonucleotides; 2009 Sep; 19(3):209-22. PubMed ID: 19653880 [TBL] [Abstract][Full Text] [Related]
14. "Fitting" makes "sensing" simple: label-free detection strategies based on nucleic acid aptamers. Du Y; Li B; Wang E Acc Chem Res; 2013 Feb; 46(2):203-13. PubMed ID: 23214491 [TBL] [Abstract][Full Text] [Related]
15. Properties of an LNA-modified ricin RNA aptamer. Förster C; Zydek M; Rothkegel M; Wu Z; Gallin C; Geßner R; Lisdat F; Fürste JP Biochem Biophys Res Commun; 2012 Mar; 419(1):60-5. PubMed ID: 22326915 [TBL] [Abstract][Full Text] [Related]
16. Aptamers and SELEX in Chemistry & Biology. Famulok M; Mayer G Chem Biol; 2014 Sep; 21(9):1055-8. PubMed ID: 25237853 [TBL] [Abstract][Full Text] [Related]
17. The development and testing of aptamers for cancer. Barbas AS; White RR Curr Opin Investig Drugs; 2009 Jun; 10(6):572-8. PubMed ID: 19513946 [TBL] [Abstract][Full Text] [Related]
18. Assays for aptamer-based platforms. Citartan M; Gopinath SC; Tominaga J; Tan SC; Tang TH Biosens Bioelectron; 2012 Apr; 34(1):1-11. PubMed ID: 22326894 [TBL] [Abstract][Full Text] [Related]